Avenue Therapeutics (ATXI) Q1 2025 earnings summary

Executive summary

• Net loss for Q1 2025 was $1.9 million, a 57% improvement year-over-year from $4.3 million in Q1 2024, primarily due to reduced R&D expenses following the termination of the AJ201 program.

• Accumulated deficit as of March 31, 2025, was $104.4 million; the company continues to operate at a loss and expects to do so for the foreseeable future.

• Nasdaq delisted Avenue Therapeutics' common stock in March 2025 due to insufficient stockholders' equity; shares now trade OTC under the symbol ATXI.

• The AnnJi License Agreement for AJ201 was terminated in April 2025, with Avenue transferring all rights back to AnnJi and receiving a $2 million payment and potential future milestone and royalty payments.

Financial highlights

• Research and development expenses decreased 83% to $0.4 million in Q1 2025 from $2.4 million in Q1 2024, mainly due to the cessation of AJ201 development.

• General and administrative expenses increased 14% to $1.5 million, driven by higher legal costs.

• Net cash used in operating activities was $1.2 million, while $2.1 million was raised through ATM equity sales.

• Cash and cash equivalents at March 31, 2025, totaled $3.5 million, up from $2.6 million at year-end 2024.

Outlook and guidance

• Management expects continued operating losses and negative cash flows as product candidates advance through development.

• Additional financing will be required to fund operations beyond the next 12 months; no assurance of obtaining capital on favorable terms.

• No plans to initiate the Phase 3 IV tramadol study without new funding; strategic alternatives for Baergic/BAER-101 are being explored.